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Abstract 
Liver-on-a-Chip technology holds considerable potential for applications in drug screening and 
chemical-safety testing. To establish such platforms, functional hepatocytes are required; however, 
primary hepatocytes are commonly used, despite problems involving donor limitations, lot-to-lot 
variation, and unsatisfactory two-dimensional culture methods. Although human pluripotent stem cells 
(hPSCs) may represent a strong alternative contender to address the aforementioned issues, remaining 
technological challenges include the robust, highly efficient production of high-purity hepatic clusters. In 
addition, current Liver-on-a-Chip platforms are relatively complicated and not applicable for 
high-throughput experiments. Here, we develop a very simple Liver-on-a-Chip platform with mature and 
functional hepatocyte-like cells derived from hPSCs. To establish a method for hepatic differentiation of 
hPSCs, cells were first treated by inhibiting the phosphoinositide 3-kinase- and Rho-associated protein 
kinase-signaling pathways to stop self-renewal and improve survival, respectively, which enabled the 
formation of a well-defined endoderm and facilitated hepatocyte commitment. Next, a simple 
microfluidic device was used to create a three-dimensional (3D) culture environment that enhanced the 
maturation and function of hepatocyte-like cells by increasing the expression of both hepatic maturation 
markers and cytochrome P450. Finally, we confirmed improvements in hepatic functions, such as drug 
uptake/excretion capabilities, in >90% of 3D-matured hepatocyte-like cells by indocyanin green assay. 
These results indicated that the incorporation of hPSC-derived hepatocytes on our Liver-on-a-Chip 
platform may serve to enhance the processes involved in drug screening and chemical-safety testing. 
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Introduction 
Organs-on-a-Chip (OoC) platforms hold considerable potential for pre-clinical trials of drug 
development1–3 as well as toxicological tests.4 To date, such testing has relied upon animal models; 
however, large challenges remain with regard to predicting the safety and efficacy of drug candidates for 
human clinical use. Therefore, new in vitro models need to be developed as an alternative to animal 
models to predict treatment effects on humans with high predictability. OoCs represent the most suitable 
platforms to fulfill these requirements, as these platforms were developed to recapitulate human 
physiological conditions in vitro. Currently, numerous OoC platforms have been reported as 
representative of organs, such as the brain,5 lung,6,7 heart,8,9 gut,10,11 intestine,12 liver13–16 or multiple 
tissues.17–19 Considering that the liver constitutes the largest organ in the human body and has many 
critical roles for body maintenance as well as drug metabolism and detoxification, we focused on 
optimizing the Liver-on-a-Chip platform, as the reported platform still retains two critical issues 
involving cell sources and cell culture methods.  
In terms of cell source, hepatocytes, which constitute the majority of cells in the liver, are mainly used 
for current drug screening and toxicological testing as well as Liver-on-a-Chip platforms. Primary 
hepatocytes can be obtained from healthy donors; however, these cells cannot proliferate under standard 
cell-culture conditions and often experience loss of function. As an alternative, established cell lines are 
used for cell culture and in vitro drug testing, although these cells were often originally harvested from 
tumors and do not represent healthy liver functions. Therefore, obtaining sufficient amounts of proper and 
functional hepatocytes remains challenging. 
To meet this requirement, human pluripotent stem cells (hPSCs), such as embryonic (hESCs20) and 
induced pluripotent stem cells (hiPSCs21) hold considerable potential as sources to generate hepatocytes. 
hPSCs exhibit two distinctive capabilities: unlimited self-renewal without karyotypical abnormality and 
the ability to differentiate into almost any cell type. These capabilities allow for the generation of 
hepatocyte quantities sufficient for subsequent applications such as Liver-on-a-Chip platforms. 
However, there remain issues with current methods related to the induction of hepatic differentiation 
from hPSCs to result in functional and mature hepatocytes. These methods involve either 1) formation of 
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embryoid bodies or cell aggregates,22 or 2) introduction of exogenous genes (e.g., HHEX23 and SOX1724). 
Such methods have high potential to cause quality control difficulties involving contamination with other 
differentiated cells; moreover, the hepatic functionality of the resultant cells still has considerable room 
for improvement. Therefore, it is necessary to establish a novel method enabling the efficient and robust 
differentiation of hPSCs into functional hepatocytes.  
In addition to cell sources, cell culture methods also require new innovation. Although 
two-dimensional (2D) culture of hepatocytes has been carried out for many years, this method is also 
problematic; for example, primary hepatocytes often lose their function under 2D culture. Therefore, a 
number of reports have suggested the use of three-dimensional (3D) culture methods to render 
hepatocytes more functional.25 Moreover, recent studies have shown that organoids26–28 hold promise to 
obtain micro live tissues with greater functionality than those of 2D culture. However, the described cell 
aggregates and organoids exhibited varying size and structure as they are reliant upon only the capacity of 
the stem cells for tissue formation, resulting in low reproducibility. Therefore, these methods have yet to 
reach an acceptable stage for use in drug screening. Similarly, the majority of conventional 
Liver-on-a-Chip platforms were based on 2D cell culture. Moreover, as most previously developed 
Liver-on-a-Chip platforms are both sophisticated and complicated and require special instruments to 
control the procedures, they are not user-friendly, limiting their use by general biology laboratories and 
their applicability for drug screening owing to the lack of high-throughput screening capability. 
Fig. 1. The hepatic differentiation process from human pluripotent stem cells. A variety of solutions containing basal medium, growth factors, and 
chemicals were administered to hPSCs to efficiently induce differentiation to hepatocyte-like cells. Initially, hPSCs were treated with mTeSR-1 medium 
supplemented with combinations of Activin A, BMP-4, CHIR99021 (CHIR), LY294002 (LY), and Y27632 (Y) to induce definitive endoderm (DE) 
differentiation until Day 4 (d4). Then, cells were treated with Activin A in RPMI medium supplemented with B27 for anterior definitive endoderm (ADE) 
specification until Day 8. As the next step, cells were treated with BMP-4 and FGF-10 for inducing hepatocyte commitment in RPMI medium 
supplemented with B27 until Day 11. Finally, cells were treated with oncostatin M (OSM) and hepatocyte growth factor (HGF) in hepatocyte basal 
medium for hepatocyte maturation. 
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Here, we developed a novel Liver-on-a-Chip platform by 1) establishing a protocol enabling the 
efficient differentiation of hepatocyte-like cells from hPSCs, resulting in high degrees of purity and 
reproducibility, and 2) applying a simple microfluidic 3D cell-culture platform29,30 (Fig. 1). To 
facilitate efficient hepatic differentiation and cell survival, our method utilizes a cocktail of 
chemicals and growth factors. Conversely, our method does not require the use of exogenous genes, 
thereby eliminating concerns of genetic integration into host cells and variations in gene-delivery 
efficiency. After hepatic differentiation from hPSCs to hepatic progenitor cells, the cells are 
introduced into our simple microfluidic 3D cell culture device to prepare our Liver-on-a-Chip 
platform with hPSC-derived hepatocyte-like cells of high-maturation status. Notably, this platform 
does not require any special instruments, with standard pipettes able to be used to carry out the 
experiments. 
 
Results and discussion 
Cell survival and robustness of definitive-endoderm (DE) differentiation is enhanced by 
phosphoinositide 3-kinase (PI3K) and Rho-associated protein kinase (ROCK) inhibition 
Induction of DE differentiation is the most critical step required to promote further differentiation (Fig. 2). 
In this process, transforming growth factor (TGF)- ,31,32 bone morphogenetic protein (BMP)-4,33 
 -catenin,34,35 and basic fibroblast growth factor (bFGF)32,36-signaling pathways play critical roles. 
Moreover, the PI3K-signaling pathway is critical for the maintenance of hPSC self-renewal,37,38 with 
inhibition of this pathway resulting in hPSC differentiation. Previously, Hannan et al. established a 
method to effectively achieve hPSC differentiation to DE using a cocktail of activin A, BMP-4, bFGF, 
LY294002, and CHIR99021, but without the use of exogenous genes.39 However, this method results in 
massive cell death and inefficient and irreproducible outcomes. Furthermore, the use of hPSC aggregates 
is unlikely to allow improved robustness, owing to the challenge associated with size control, which is a 
critical factor for lineage determination during hPSC differentiation. Although the use of dissociated 
hPSCs may improve robustness, the related processes continue to result in large amounts of cell death. 
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Therefore, we used a ROCK inhibitor (Y27632) that has previously been used to facilitate the survival 
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of dissociated, self-renewing hPSCs.40 We hypothesized that administration of a ROCK inhibitor would 
also facilitate cell survival during the early stage of DE differentiation. For the medium, we modified 
mTeSR-1-defined medium41 containing BMP- and bFGF (Fig. 1 and Supplementary Table S1), which 
Fig. 2. Combination of ROCK (10 µM Y27632) and PI3K (10 µM LY294002) inhibitors facilitates survival and inhibits self-renewal of hPSCs during 
definitive-endoderm (DE) differentiation. (A) 1-day treatment with mTeSR-1 basal medium in combination with Y27632 increases cell survival of H9 
human embryonic stem cells (hESCs). Data represent the means ± standard deviation (n = 3). (B, C) Both dissociated and clumped H9 hESCs treated with 
mTeSR-1/Y27632 were able to proliferate during DE differentiation (B) with similar doubling times (C). Data represent the means ± standard deviation (n 
= 3). “n.s.” represents “not significant”. (D) Selection of mTeSR-1 or CDM-PVA medium to induce differentiation of dissociated or clumped H9 hESCs 
into DE by monitoring the expression levels of the CXCR4 DE marker. Cells treated with mTeSR-1 medium supplemented with activin A, BMP-4, 
LY294002, and CHIR99021, along with Y27632 showed a more homogeneous cell population with higher CXCR4 expression. (E) Initial cell density 
influences the cellular heterogeneity during DE differentiation, as determined by CXCR4 expression. (F) Initial cell density is inversely correlated with 
expression levels of the SOX17 DE marker. At low initial cell density, SOX17 expression levels varied among experiments. Data represent the means ± 
standard deviation (n = 3). “n.s.” represents “not significant”. (G) Representative gel electrophoresis of RT-PCR samples to ascertain expression of 
α-fetoprotein (AFP) and hepatocyte nuclear factor 4α (HNF4A) differentiation marker expression on day 12. GAPDH, a housekeeping gene, was used as an 
internal control. Data were obtained from three independent experiments. N.C. represents a negative control (water). 
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are also commonly used as key factors to introduce DE differentiation. We observed that hPSCs showed 
unstable behavior following introduction of the new culture conditions; therefore, for establishing robust 
differentiation protocols, the initial use of self-renewing culture medium was beneficial, followed by 
gradually changing to the differentiation medium. Toward this end, activin A, BMP-4, LY294002, and 
CHIR99021 were subsequently added into the mTeSR-1 medium for DE differentiation. 
To confirm increases in cell survival during DE differentiation, we counted H9 hESCs20 following 1 
day of treatment (Fig. 2A). Cells treated with both 10 µM Y27632 and 10 µM LY294002 showed 
significant increases in cell number, as compared with levels observed in cells treated with only 
LY294002. This result indicated that inhibition of the ROCK-signaling pathway improved cell survival to 
a degree greater than that observed following inhibition of the PI3K-signaling pathway.  
We then investigated differences in outcomes based on initiating differentiation from either dissociated 
or clumped hPSCs according to cell number and doubling time (Fig. 2B and C). We observed that 
following a 5-day incubation with 10 µM Y27632 and 10 µM LY294002 and DE differentiation, both 
dissociated and clumped hESCs increased cell numbers with similar doubling times. These results 
suggested that Y27632 improves cell survival even during DE differentiation, but not cell proliferation. 
To confirm cell status following DE differentiation, the expression of C-X-C-motif chemokine 
receptor-4 (CXCR4), a cell surface DE-differentiation marker, was quantitatively analyzed by flow 
cytometry (Fig. 2D) and compared with levels measured in previously-reported chemically defined 
medium (CDM-PVA)39 (Supplementary Table S2). Both H9 and 253G1 cells treated with 
mTeSR-based medium showed higher degrees of purity and enhanced CXCR4 expression (99.6%) 
compared to those of cells cultured in CDM-PVA medium (81.5%). Then, we investigated the effects of 
initial cell-seeding density on the induction of DE differentiation (Fig. 2E). During 5-day DE 
differentiation, cell numbers in all cell densities increased approximately 10 fold (Fig. 2B); however, the 
increase in initial cell number revealed bimodal cell populations with regard to CXCR4 expression (Fig. 
2E). These results indicated that the use of a smaller initial cell-seeding density resulted in a more 
homogeneous cell population with higher CXCR4 expression.  
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We also measured expression of the sex-determining region Y box-17 (SOX17) transcription factor and 
endoderm-lineage marker by quantitative reverse transcription-polymerase chain reaction (RT-PCR) (Fig. 
2F). The use of cell clumps resulted in higher SOX17 expression as compared with using dissociated cells, 
with SOX17 expression subsequently decreasing along with increasing cell numbers, although lower 
initial cell-seeding density (2.5 × 104 cells cm−2) resulted in large variations in SOX17 expression. We 
also confirmed hepatocyte differentiation by monitoring the expression of  -fetoprotein (AFP) and 
hepatocyte nuclear factor 4  (HNF4A  differentiation marker mRNA on day 12 (Fig. 2G). The use of cell 
aggregates with lower initial cell-seeding density (2.5 × 104 cells cm−2) did not result in AFP and HNF4A 
expression. Based on these results, we used 5 × 104 cells cm−2 for further differentiation protocols 
consequent to our observation of higher purity and improved robustness at higher initial cell densities. 
Under the optimized conditions, we tested DE differentiation from 253G1 hiPSCs42 and differentiation to 
highly pure CXCR4-positive DE cells, and found that this condition gave similar results as H9 hESCs, 
even with 253G1 hiPSCs (Supplementary Fig. S1). 
 
Optimization to induce anterior definitive-endoderm (ADE) specification and hepatocyte 
commitment (HC) 
We established a robust and efficient procedure for ADE specification from DE cells, as well as HCs, to 
generate hepatic progenitor cells (Fig. 3 and Supplementary Table S1). For ADE specification as shown 
in Fig. 1 and Experimental, it was necessary to maintain activin A levels but remove bFGF to reduce 
active cell-signaling pathways and maintain pluripotency.43 Alternatively, HC requires BMP4 and FGF10 
signaling.44 ADE specification and HC require several days to achieve treatment-induced changes in 
phenotype. Therefore, we treated cells with activin A and a combination of BMP4 and FGF10 in RPMI 
medium supplemented with B27 supplement for ADE and HC, respectively, and varied these treatment 
periods to identify the optimal timing (~1–3 days for ADE and ~1–4 days for HC) for hepatic progenitor 
cell differentiation (Fig. 3A) by observing the expression levels of genes associated with each 
differentiation phenotype following treatment as determined by quantitative RT-PCR (Fig. 3B and 
Supplementary Table S3).  
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Following 1 day of treatment for ADE specification, cells continued to express most of the 
pluripotency associated genes including NANOG, SOX2, and OCT4 (or POU5F1) (Fig. 3B, 
“Pluripotency”). However, when the treatment for ADE specification was extended to 3 days, the 
expression levels of pluripotency associated genes was decreased, whereas that of genes associated with 
extraembryonic endoderm (SOX7, LAMB1, and HNF1A), mesoendoderm (GSC and NODAL), endoderm 
(FOXA2, SOX17, CXCR4, HNF1B, and HNF4A), and early hepatic cells (AFP, CYP3A7, DLK1, PROX1, 
and TBX3) was increased. Although 1-day treatment for ADE specification did not induce expression of 
genes associated with hepatic nuclear receptors and/or transporters, expression of these genes was 
observed on days ~2 and ~3. These results indicated that 3 and 4 days of treatment for ADE and HC, 
respectively, were optimal to obtain hepatic progenitor cells.  
 
Fig. 3. Quantitative RT-PCR analysis reveals optimal periods for anterior definitive endoderm (ADE) specification and hepatocyte commitment. (A) 
Tested periods for ADE specification and hepatocyte commitment. (B) Gene-expression patterns of 253G1 hiPSCs treated for ADE specification and 
hepatocyte commitment. (1, 2) represents 1-day treatment of ADE specification and 2-day treatment for hepatocyte commitment. Center lines show 
the medians; box limits indicate 25% and 75%; whiskers extend 1.5 times the interquartile range from 25% and 75%. These experiments were carried 
out at least three times independently. 
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Evaluation of hepatocyte differentiation status by observing gene-expression patterns 
To confirm the gene expression associated with hepatic differentiation, we conducted multiplex 
quantitative RT-PCR, followed by clustering analysis (Fig. 4, Supplementary Fig. S2 and 
Supplementary Table S3). Clustering analysis based on gene-expression patterns resulted in six clusters. 
Class 1 genes in the undifferentiated cells exhibited the highest expression levels, which decreased after 
the initiation of differentiation. Most Class1 genes, including NANOG, SOX2, and POU5F1, were 
associated with pluripotency. Class 2 included endoderm genes, such as CXCR4, GATA6, and SOX17, 
which exhibited peak expression at day 5. Class 3 included early hepatic genes, such as DLK1 and TBX3, 
which exhibited peak expression at day 12, as well as some genes associated with the cytochrome P450 
(CYP) family (CYP1A2, CYP2D6, and CYP2E1). Class 4 included many hepatic genes, such as AHSG, 
APOA4, and HNF1A, as well as hepatic transporter genes and solute-carrier-family genes, such as 
SLC10A1, SLC22A1, and SLC22A2, and exhibited the highest levels of expression at days 20 or 24. Class 
5 genes, including AQP1, B2M, CD9, CYP2C8, NR3C1, SLC22A2, and SOX7, showed the highest 
expression at day 30, but did not appear to exhibit functional enrichment. Class 6 showed unique 
gene-expression patterns, with genes initiating expression on day 20 and peaking at day 35. These 
includes hepatic genes, such as ALB, SERPINA, and TAT, as well as other early hepatic genes. These 
gene-expression data suggested that our hepatic differentiation method resulted in a natural 
developmental process.  
Fig. 4. Gene-expression analysis investigating the overall gene-expression signatures from pluripotent status to hepatocyte differentiation. Clustering 
analysis based on 96 gene expression patterns divided the tested genes into six clusters. An expression trend for each group during the 
hepatocyte-differentiation process is also plotted. 
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 Differences in gene expression between hPSC-derived hepatocyte-like cells and liver lysate 
To investigate similarities between mature liver and cultured cells, we compared gene-expression patterns 
between hPSC-derived hepatocyte-like cells and mature liver lysate (Fig. 5 and Supplementary Table 
S3 and S4) using hPSC-derived hepatocyte-like cells at days 0, 24, and 35 of differentiation and liver 
lysate from a healthy donor. Hepatic marker genes, such as ALB and HNF4A, exhibited significant 
increases during the culture process, indicating progression of differentiation and increasing similarity 
between hPSC-derived hepatocyte-like cells and mature liver lysate. Additionally, genes including AFP, 
APOA4, KRT7, KRT8, KRT18, KRT19, DLK1, GATA6, and HNF1B exhibited increased expression 
between days 0 and 24, which was higher than the expression of these genes observed in the liver lysate. 
AFP is a marker of hepatoblasts and fetal livers, and APOA4 exhibits high expression levels in fetal liver. 
KRT7, KRT8, KRT18, and KRT19 are expressed in cholangiocytes, DLK1 is a hepatic 
progenitor-cell-surface marker, and GATA6 and HNF1B are transcription factors. Specifically, both AFP 
and DLK1 were strongly expressed in the hPSC-derived cells to a greater degree than in liver lysate, 
indicating that these cells did not reach the status mature adult liver. However, genes from the CYP 
family in hPSC-derived cells exhibited lower expression levels relative to those observed in liver lysate, 
suggesting that our method requires improvement in terms of CYP-family expression. 
 
Fig. 5. Comparison of gene-expression patterns between hepatocyte-like cells derived from 253G1 hiPSCs and liver lysate. Genes associated with 
hepatic, hepatoblast, and cytochrome P450 (CYP) family genes were measured by quantitative RT-PCR. Gene-expression values were normalized using 
the values from liver lysate genes as standards. These experiments were carried out at least three times independently. 
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Matured hPSC-derived hepatocyte-like cells in the Liver-on-a-Chip 
To facilitate maturation levels for establishment of the Liver-on-a-Chip platform, we developed a simple 
3D-culture method using a microfluidic device. We hypothesized that 3D-culture conditions would 
provide a more suitable environment for hepatocytes as compared with conventional 2D-culture 
methods27 toward mimicking 3D micro liver tissues (Fig. 6A). Previously, we reported a microfluidic 
device enabling 3D culture of hPSCs29,30 (Fig. 6B), which was utilized in the present study to perform 3D 
culturing of hepatocyte-like cells from day 12 to enhance the maturation process. The microfluidic device 
was made of polydimethylsiloxane (PDMS), which exhibits good biocompatibility and gas 
Fig. 6. Simple Liver-on-a-Chip platform with matured hPSC-derived hepatocyte-like cells. (A) Illustration of 2D and Liver-on-a-Chip 3D cultures for 
hepatocyte maturation. (B) Photograph of a microfluidic 3D-culture device29,30 for the Liver-on-a-Chip platform and the structure of a microfluidic 
cell-culture chamber [10 mm (L) × 1.5 mm (W) × 150 µm (H)] with a cell inlet (0.75-mm diameter) and medium reservoir (3-mm diameter). (C) 
Immunocytochemistry to visualize the hepatocyte-maturation marker α1 anti-trypsin (A1AT) in H9 hESC-derived hepatocyte-like cells. “2D” and “3D” 
represent hepatocyte-like cells derived from H9 hESCs cultured in a conventional 35-mm culture dish and a microfluidic 3D cell-culture device, 
respectively. Scale bar represents 20 µ m. (D) Representative gel electrophoresis of RT-PCR products for mRNAs associated with the cytochrome P450 
family (e.g., CYP3A4, CYP1A1, CYP2A9, CYP2C19, and CYP2D6), ATP-binding cassette (ABC) transporters (MRP2 and MDR/TAP), 
hepatocyte-maturation markers (Albumin, UGT1A1, A1AT, and TDO1), and endoderm markers (AFP and HNF4A), obtained from independently 
triplicated experiments. HepG2 hepatocellular carcinoma cells were used as a control, and a liver extract from a healthy donor was used as a positive 
control. H9_Hep and Undif_H9 represent hepatocyte-like cells derived from H9 hESCs and undifferentiated H9 hESCs, respectively. (E) 
Microphotographs of 2D- and microfluidic 3D-hepatocyte-like cells treated with indocyanine green (ICG) for 1 h to visualize ICG uptake and then 
excretion after 24 h. Scale bar represents 500 µm. 
 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/232215doi: bioRxiv preprint first posted online Dec. 13, 2017; 
permeability,47 and contained two microfluidic 3D cell-culture chambers [10 mm (L) × 1.5 mm (W) × 
150 µm (H)] with a cell inlet (0.75-mm diameter) and a medium reservoir (3-mm diameter). To confirm 
the maturity of hPSC-derived hepatocyte-like cells at the protein level, we conducted 
immunocytochemistry for one of the maturation markers,  1 anti-trypsin (A1AT). Our results indicated 
that the A1AT hepatocyte-maturation marker was more strongly expressed in 3D-cultured hepatocyte-like 
cells derived from H9 hESCs over 33 days using our method as compared with levels observed in 
2D-cultured cells (Fig. 6C and Supplementary Fig. S3). Although undifferentiated H9 hESCs did not 
express hepatic genes, we also confirmed increased mRNA expression of other hepatocyte-marker genes, 
such as UGT1A1, CYP3A4, CYP2A9, CYC2C19, and CYP2D6, in the 3D-cultured H9 hESC-derived 
hepatocyte-like cells relative to levels observed in 2D-cultured cells (Fig. 6D and Supplementary Table 
S5). In contrast, HepG2 cells did not express UGT1A1, TDO1, MDR/TAP, CYP3A4, CYP2A9, CYP2C19, 
or CYP2D6. As expected, the liver extract from the healthy donor strongly expressed all tested genes at 
levels exceeding those of hepatocyte-like cells derived from H9 hESCs. These results indicated that the 
hepatocyte-like cells derived from H9 hESCs exhibited improved gene expression relative to a HepG2 
cell line and 2D-cultured hepatocyte-like cells, but were unable to match levels observed in liver extracts 
from a healthy donor.  
To investigate differences in functionality, an uptake/excretion assay for indocyanine green (ICG), 
which is a non-invasive marker of drug uptake/excretion in the liver,45,46 was performed on cells from 
both 3D- and 2D cultures (Fig. 6E and Supplementary Fig. S4). Notably, 3D-cultured cells showed 
greater ICG uptake within 1 h compared to that of 2D-cultured cells, with most cells also effectively 
excreting the ICG after 24 h. These results indicated that hPSC-derived hepatocyte-like cells in the 
Liver-on-a-Chip microfluidic 3D culture device appeared more mature and functional, compared with 
those of 2D-cultured cells. 
 
Experimental 
hPSC culture. hESCs were used according to the guidelines of the ethnical committee of Kyoto 
University. H9 hESCs were purchased from WiCell Research Institute (Madison, WI, USA). 253G1 
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hiPSCs were provided by RIKEN BioResource Research Center (Ibaraki, Japan). H9 hESCs and 253G1 
hiPSCs were used in this study. Prior to culturing, hESC-certified Matrigel (Corning, Corning, NY, USA) 
was diluted with Dulbecco’s modified Eagle medium (DMEM)/F12 medium (Sigma-Aldrich, St. Louis, 
MO, USA) at a 1:75 (v/v) ratio and coated onto a culture dish. Matrigel was incubated in a dish for 24 h 
at 4°C. Then, excess Matrigel was removed and the coated dish was washed with fresh DMEM/F12 
medium. 
mTeSR-1-defined medium (Stem Cell Technologies, Vancouver, Canada) was used for daily 
culturing of hPSCs. For passaging, cells were dissociated with TrypLE Express (Life Technologies, 
Carlsbad, CA, USA) for 3 min at 37°C and harvested. A cell strainer was used to remove undesired cell 
aggregates from the cell suspension, and cells were centrifuged at 200 × g for 3 min and resuspended in 
mTeSR-1 medium. Cells were counted using a NucleoCounter NC-200 (Chemetec, Baton Rouge, LA, 
USA). mTeSR-1 medium containing 10 µM of the ROCK inhibitor Y-27632 (Wako, Osaka, Japan) was 
used to prevent apoptosis of dissociated hPSCs on day 1. mTeSR-1 medium without the ROCK inhibitor 
was used on subsequent days, with daily medium changes. 
Hepatic differentiation from hPSCs. Prior to inducing differentiation, a cell-culture dish was coated 
with 0.1% gelatin in phosphate-buffered saline (PBS) at 25°C room temperature for 30 min. The gelatin 
solution was then aspirated and DMEM/F12 medium (Sigma-Aldrich) supplemented with 10% (v/v) fetal 
bovine serum (FBS), penicillin/streptomycin, and 100 µM  -mercaptoethanol (Sigma-Aldrich) was 
introduced onto the culture dish for serum coating at 37°C for 24 h. The coated dish was then rinsed with 
fresh medium. 
To induce endoderm differentiation, cultured hPSCs were washed with PBS and treated with TryPLE 
Express at 37°C for 5 min, followed by the addition of basal medium and transfer of the cell suspension 
into a 15-mL tube. Cells were centrifuged at 200 × g for 3 min and the supernatant was removed. Cells 
were resuspended in mTeSR-1 medium supplemented with 10 µM Y27632 and 100 ng mL−1 activin A, 
plated on a serum-coated culture dish, and cultured in a humidified incubator at 37°C with 5% CO2 for 24 
h. At the end of day 1, the medium was replaced with fresh mTeSR-1 medium supplemented with 10 µM 
Y27632 and 100 ng mL−1 activin A and cultured for another 24 h. On day 2, the medium was replaced 
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with mTeSR-1 medium supplemented with 10 µM Y27632, 100 ng mL−1 activin A, 10 ng mL−1 BMP-4, 
10 µM LY294002, and 3 µM CHIR99021, and cells were incubated for 24 h. On day 3, medium was 
replaced with mTeSR-1 medium supplemented with 10 µM Y27632, 100 ng mL−1 activin A, 10 ng mL−1 
BMP-4, and 10 µM LY294002, and cells were incubated for 24 h. On day 4, medium was replaced with 
Roswell Park Memorial Institute (RPMI) medium supplemented with B-27 (Life Technologies), 100 ng 
mL−1 activin A, and 100 ng mL−1 bFGF, and cells were incubated for 24 h. 
To induce ADE specification, cells were treated with RPMI medium supplemented with 50 ng mL−1 
activin A, with daily medium changes for 3 days. Cells were then treated with RPMI medium 
supplemented with 20 ng mL−1 BMP-4 and 10 ng mL−1 FGF-10, with daily medium changes for 4 days. 
On day 12, the medium was replaced with hepatocyte basal medium (Lonza, Basel, Switzerland) 
supplemented with 30 ng mL−1 oncostatin M and 50 ng mL−1 hepatocyte growth factor to induce 
maturation of the differentiated hepatocytes. Cells were incubated at 37°C, and medium was changed 
every 2 days. 
HepG2 cell culture. HepG2 cells were provided by American Type Culture Collection (Manassas, VA, 
USA). HepG2 cells were cultured with DMEM supplemented with 10% (v/v) FBS, 1% 
penicillin/streptomycin, and 1 mM nonessential amino acids, and the medium was changed every 2 to 3 
days. The cells were passaged with trypsin-EDTA solutions at a 1:10 to 1:20 subculture ratio. 
Flow cytometry. Cells were harvested with TrypLE Express and rinsed with PBS twice prior to cell 
counting. For staining with antibodies, cells were diluted to a final concentration of 1 × 107 cells mL−1 in 
PBS supplemented with 2% fetal calf serum (FCS). Fluorescence-labeled antibodies were added and 
incubated at room temperature for 30 min. As a negative control, specific isotype controls were used. 
After removing excess antibodies by centrifugation at 300 × g for 5 min, cells were washed with PBS 
containing 2% FCS, and cell suspensions were applied to a FACS Canto II (BD Biosciences, Franklin 
Lakes, NJ, USA) for flow cytometric analysis. Data analysis was performed using FlowJo software (v9; 
FlowJo, LLC, Ashland, OR, USA). 
RT-PCR. Total RNA was purified using an RNeasy Mini Kit (Qiagen, Hilden, Germany), and 1 µg of 
total RNA was reverse transcribed to generate cDNA using PrimeScript RT master mix (Perfect Real 
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Time; TaKaRa Bio, Shiga, Japan). A reaction mixture (25 µL) containing 20 ng cDNA, 0.2 µM PCR 
primers (Supplementary Table S1), and 5 U of Taq DNA polymerase (TaKaRa Bio) was subjected to 
PCR using a thermal cycler (Applied Biosystems 7300 real-time PCR system; Applied Biosystems, 
Foster City, CA, USA). PCR was performed with 30 to 35 cycles (94°C for 30 s, 58°C for 30 s, and 72°C 
for 60 s). PCR products (10  L) were electrophoresed on 1.2% agarose gels and visualized by GelRed 
nucleic acid staining (Biotium, Fremont, CA, USA).  
Quantitative RT-PCR array. As a positive control of human normal liver, Human Total Liver RNA was 
purchased from TaKaRa Bio. Total RNA (2.5 µg) was reverse transcribed to generate cDNA using 
PrimeScript RT master mix. A reaction mixture (21 µL) containing 20 ng cDNA, 12.5 µL SYBR Premix 
Ex Taq II (Tli RNaseH Plus; TaKaRa Bio), and 0.5 µL ROX reference dye was introduced into wells of a 
96-well plate of Human PrimerArray hepatic differentiation (TaKaRa Bio), according to manufacturer 
instruction, to assess hepatocyte-specific gene expression (Supplementary Table S2). PCR conditions 
included an initial incubation at 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and then 60°C for 31 
s on an Applied Biosystems 7300 real-time PCR system. 
Immunocytochemistry. Cells were fixed with 4% paraformaldehyde in PBS for 20 min at 25°C and then 
permeabilized with 0.5% Triton X-100 in PBS for 16 h at 25°C. Subsequently, cells were blocked in PBS 
(5% normal goat serum, 5% normal donkey serum, 3% bovine serum albumin, 0.1% Tween-20) at 4°C 
for 16 h and then incubated at 4°C for 16 h with the primary antibody [anti-human A1AT rabbit IgG, 
1:800; Dako, Glostrup, Denmark] in PBS with 0.5% Triton X-100. Cells were then incubated at 37°C for 
60 min with a secondary antibody (AlexaFluor 488 Donkey anti-rabbit IgG, 1:1000; Jackson 
ImmunoResearch, West Grove, PA, USA) in blocking buffer prior to a final incubation with 
4′,6-diamidino-2-phenylindole (DAPI) at 25°C for 30 min. 
Image acquisition. The sample containing cells was placed on the stage of a Nikon ECLIPSE Ti inverted 
fluorescence microscope equipped with a CFI plan fluor 10×/0.30 N.A. objective lens (Nikon, Tokyo, 
Japan), CCD camera (ORCA-R2; Hamamatsu Photonics, Hamamatsu City, Japan), mercury lamp 
(Intensilight; Nikon), XYZ automated stage (Ti-S-ER motorized stage with encoders; Nikon), and filter 
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cubes for fluorescence channels (DAPI and GFP HYQ; Nikon). For image acquisition, the exposure times 
were set at 500 ms for DAPI and 500 ms for GFP HYQ (for A1AT). 
ICG uptake/excretion assay. Briefly, 1 mg mL−1 ICG was dissolved in hepatocyte-maturation medium 
and cells were treated with ICG solution for 1 h, rinsed with hepatocyte-maturation medium, and then 
observed using a bright-field microscope (Olympus, Tokyo, Japan). After 24 h, cells were observed again 
to visualize excretion capability. 
Microfluidic device fabrication. A microfluidic device was fabricated using stereolithographic 
3D-printing techniques and solution cast-molding processes.29 The mold for the microfluidic channels 
was produced using a 3D printer (Keyence Corporation, Osaka, Japan). Sylgard 184 PDMS two-part 
elastomer (10:1 ratio of pre-polymer to curing agent; Dow Corning Corporation, Midland, MI, USA) was 
mixed, poured into a 3D-printed mold to produce a 5-mm-thick PDMS layer, and de-gassed by using a 
vacuum desiccator. The PDMS material was then cured in an oven at 65°C for 48 h. After curing, the 
PDMS form was removed from the mold, trimmed, and cleaned. The PDMS form and a glass dish or 
plastic plate were corona-plasma-treated (Kasuga Denki, Inc., Kawasaki, Japan) and bonded together by 
baking in an oven at 80°C. 
Preparation of the Liver-on-a-Chip microfluidic 3D culture device. Prior to use, a microfluidic 3D 
cell-culture device was sterilized in 70% ethanol and placed under ultraviolet light in a biosafety cabinet 
for 30 min. A microfluidic cell-culture chamber was then coated with Corning Matrigel hESC-qualified 
matrix (Corning) diluted to 1:75 (v/v) with DMEM/F12 (Sigma-Aldrich). After a 1-day incubation at 4°C, 
excess Matrigel was removed, and the coated dish was washed with fresh DMEM/F12. Cells were 
harvested using trypsin and collected in a 15-mL tube. Following centrifugation, cells were suspended in 
hepatocyte-maturation medium and introduced into a microfluidic device via a cell inlet. The microfluidic 
device was placed in a humidified incubator at 37°C with 5% CO2 atmosphere, and the medium was 
changed daily. 
Statistical analysis of gene expression. A two-tailed Student’s t-test was carried out in Microsoft Excel. 
For gene expression analysis, gene clusters were generated using normalized gene-expression values for 
the quantitative RT-PCR array by the Consensus Cluster algorithm in the R package 
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“ConsensusClusterPlus”.48 Mean values were calculated in each cluster and for each day, and fold 
changes were calculated using liver values as a standard. 
 
Conclusions 
In this study, we developed a Liver-on-a-Chip 3D culture platform with matured hPSC-derived 
hepatocyte-like cells. In particular, we firstly established an efficient and robust method to induce hPSC 
differentiation into functional hepatocyte-like cells. By optimizing the basal medium, combination of 
chemicals, and initial cell-seeding density for endoderm differentiation, we obtained a homogeneous 
population of endoderm-differentiated cells highly expressing CXCR4 from dissociated hPSCs. 
Additionally, we optimized the periods required for ADE specification and HC according to quantitative 
PCR analysis. To our knowledge, this represents the first demonstration of application of a microfluidic 
3D cell-culture platform for the maturation of hepatocyte-like cells. 
Liver-on-a-Chip platforms offer critical opportunities for drug screening and chemical-safety 
testing in a variety of industries including cosmetics and agriculture. However, there are limited 
numbers of cell sources (e.g., primary hepatocytes) available, with the number and quality varying 
by donor. Although current hepatocyte cell lines, such as HepG2, have been used as alternatives, 
they often show different characteristics from primary hepatocytes. In addition, current 2D-culture 
conditions in a chip do not allow the expression of proper hepatic functions. In this study, we 
successfully developed a Liver-on-a-Chip platform by establishing a method to induce hPSC 
differentiation into mature hepatocytes with microfluidic 3D culture to prepare functional 
hepatocyte-like cells on a chip.  
Liver-on-a-Chip platforms may be used for either “High-content analysis (HCA)” or 
“High-throughput screening (HTS)”. Although a number of Liver-on-a-Chip platforms have been 
previously reported, these often provided less information than that of current HCA, are 
exceedingly complicated for general users, and not applicable for HTS. For drug screening and 
chemical-safety testing platforms, it is necessary to decide which application would be most 
suitable at the beginning of device development. Our device and cell culture chamber are very 
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simple and offer easy handling without requiring any special instruments. They can be applicable 
for increased throughput by means of straightforward device format design, such as the use of 
microplates, following the recommendations of the recommendation of the Society for 
Biomolecular Screening (SBS). Accordingly, we consider that our Liver-on-a-Chip platform will 
fulfill current requirements and serve as a useful tool in the field of drug discovery. 
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